To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
November 2020

Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19

Vol: 9| Issue: 11| Number:21| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

N Engl J Med. 2020 Oct 28.

Contributing Authors:
P Chen A Nirula J Morris B Heller RL Gottlieb J Boscia G Huhn B Mocherla V Stosor AC Adams J Van Naarden KL Custer L Shen M Durante G Oakley AE Schade J Sabo DR Patel P Klekotka DM Skovronsky BLAZE-1 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Four hundred and fifty two patients who tested positive for coronavirus disease 19 (COVID19) were randomized to receive a single intravenous infusion of LY-CoV555, at a dose of 700mg, 2800mg, or 7000mg, or placebo, for the reduction of viral load and amelioration of symptoms. The primary outcome of interest was the change from baseline in viral load at 11 days follow up. Secondary outcomes of inte...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue